| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JACI.2010.03.028 |
| P698 | PubMed publication ID | 20513524 |
| P2093 | author name string | Elliot Israel | |
| Michael E Wechsler | |||
| Sophia Kim | |||
| Gautham Marigowda | |||
| Eyal Oren | |||
| P433 | issue | 6 | |
| P921 | main subject | Churg-Strauss syndrome | Q32811 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1336-1343 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome | |
| P478 | volume | 125 |
| Q41307296 | Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis |
| Q26866943 | Anti-IL5 therapy for asthma and beyond |
| Q41605623 | Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma |
| Q24241555 | Anti-cytokine therapies for primary systemic necrotizing vasculitis |
| Q47848286 | Biologic Agents for the Treatment of Hypereosinophilic Syndromes |
| Q35565533 | Biologic therapies targeting eosinophils: current status and future prospects |
| Q38240474 | Biological Modulators in Eosinophilic Diseases. |
| Q38763327 | Biologics for the treatment of autoimmune renal diseases. |
| Q36139731 | Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8 |
| Q36287381 | Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab |
| Q42426990 | Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery |
| Q37921646 | Churg-strauss syndrome: an update |
| Q28393792 | Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides |
| Q49722360 | Cutaneous Manifestations of Reactions to Biologics |
| Q60907829 | Eosinophilia and Kidney Disease: More than Just an Incidental Finding? |
| Q52611171 | Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies. |
| Q87695864 | Eosinophilic Lung Disease: Accompanied with 12 Cases |
| Q49567785 | Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) |
| Q40064071 | Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. |
| Q38269017 | Eosinophilic granulomatosis with polyangiitis: an overview |
| Q87407558 | Eosinophilic pneumonias |
| Q36607847 | Eosinophils and disease pathogenesis |
| Q33607031 | Eosinophils in Autoimmune Diseases. |
| Q36847447 | Eosinophils in vasculitis: characteristics and roles in pathogenesis |
| Q34769419 | Eosinophils: offenders or general bystanders in allergic airway disease and pulmonary immunity? |
| Q64119313 | Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis |
| Q30240787 | Gastrointestinal aspects of vasculitides |
| Q35490676 | IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis |
| Q40959893 | IgG4-related Disease: 2013 Update |
| Q36484399 | Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity |
| Q28067081 | Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs |
| Q49025332 | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis |
| Q30455019 | Leukotriene Inhibitors in Sinusitis |
| Q88642098 | Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome |
| Q38818682 | Management of Small Vessel Vasculitides |
| Q60045995 | Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy |
| Q28080207 | Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential |
| Q35446671 | Mepolizumab in eosinophilic disorders |
| Q38780534 | Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis |
| Q36977252 | Mepolizumab. |
| Q38646902 | Mepolizumab: First Global Approval |
| Q37820047 | New pathophysiological insights and treatment of ANCA-associated vasculitis |
| Q38135271 | New-generation therapy for ANCA-associated vasculitis |
| Q26799600 | Novel Therapies for Eosinophilic Disorders |
| Q34444620 | Novel targeted therapies for eosinophil-associated diseases and allergy |
| Q36763565 | Novel targeted therapies for eosinophilic disorders |
| Q33876003 | Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. |
| Q28073074 | Personalized Medicine in Allergy |
| Q37846670 | Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody |
| Q26778683 | Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases |
| Q21195258 | Progress in treatment of ANCA-associated vasculitis |
| Q50076914 | S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis |
| Q64071641 | Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis |
| Q27016035 | Tailored therapy for severe asthma |
| Q56535692 | Targeting cytokines to treat asthma and chronic obstructive pulmonary disease |
| Q92485478 | Targeting eosinophils: severe asthma and beyond |
| Q52571066 | Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. |
| Q37019844 | The Immunologic Mechanisms of Eosinophilic Esophagitis. |
| Q35857340 | Therapeutic approaches to patients with hypereosinophilic syndromes |
| Q37059851 | Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer |
| Q88687918 | Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review |
| Q33441880 | Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. |
| Q36206063 | Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). |
| Q85397954 | [Update Churg-Strauss syndrome] |
Search more.